Arctic Bioscience Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Christer Valderhaug

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.06%
Durata media del management	6.2yrs
Durata media del Consiglio di amministrazione	5.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Christer Valderhaug (52 yo)

no data

Mandato

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Harald Nordal	Co-Founder & Chairman	9.1yrs	Nessun dato	0.079% € 3.5k
Christer Valderhaug	Chief Executive Officer	no data	Nessun dato	0.055% € 2.4k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.6yrs	Nessun dato	1.83% € 80.6k
Jone Slinning	Chief Financial Officer	2.6yrs	Nessun dato	0.052% € 2.3k
Per Sæbo	Chief Operating Officer	12.3yrs	Nessun dato	0.090% € 4.0k
Daniele Mancinelli	Chief Technical Officer	12.3yrs	Nessun dato	0.0079% € 346.6
Steffen Eidal	Senior Vice President of Sales & Marketing	2.6yrs	Nessun dato	Nessun dato
Yuming Feng	Executive Vice President of Global Business Development	6.2yrs	Nessun dato	Nessun dato
Runhild Gammelsæter	Global Medical Director	5.3yrs	Nessun dato	0.14% € 6.0k

6.2yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 9TD è esperto e expertise (durata media dell'incarico 6.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Harald Nordal	Co-Founder & Chairman	9.1yrs	Nessun dato	0.079% € 3.5k
Jostein Dalland	Independent Board Member	4.7yrs	Nessun dato	Nessun dato
Tore Andreas Tonseth	Board Member	3.8yrs	Nessun dato	Nessun dato
Asbjorn Solevagseide	Board Member	5.6yrs	Nessun dato	Nessun dato
Jan Vartdal	Board Member	9.1yrs	Nessun dato	4.1% € 180.4k
Per Eggesbo	Board Member	8.8yrs	Nessun dato	Nessun dato
Hu Cao	Board Member	3.8yrs	Nessun dato	Nessun dato
Marita Holstad	Director	3.8yrs	Nessun dato	Nessun dato

5.1yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 9TD sono considerati esperti (durata media dell'incarico 5.1 anni).

Arctic Bioscience Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Recent updates

Arctic Bioscience AS Provides Revenue Guidance for the Year 2024

New major risk - Market cap size

Arctic Bioscience Announces Top-Line Results from Phase 2b HeROPA Study

New major risk - Financial position

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings released: kr1.79 loss per share (vs kr1.39 loss in FY 2022)

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings released

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media